Study Evaluating Occupational Exposure to Antineoplastic Drugs — BRIC  

Cytotoxicity Clinical Trial

Official title: Multicentric Study to Evaluate Occupational Exposure to Antineoplastic Drugs Through Genotoxics Markers and Enviromental Monitoring

Status Recruiting

Clinical Trial Summary

The multicenter study involves comparing two groups (an exposed group and a control group). The exposed group is selected from workers who perform their activities in drug handling areas (DH) or units for antineoplastic preparation (UFA), while the control group involves the voluntary participation of non-exposed workers (administrative staff). The control group is selected based on the characteristics of the exposed group to ensure a homogeneous sample in terms of size and characteristics.

Clinical Trial Description

The study will be proposed to all workers exposed to cytotoxic agents who have an employment contract or similar arrangement and who are affiliated with the hospital facilities participating in the protocol. Participation of workers in the study is voluntary. The control group will be recruited from administrative staff and/or individuals not exposed to chemotherapy who have an employment contract or similar arrangement and who are affiliated with the hospital facilities participating in the protocol. A subject is considered enrolled after signing the informed consent and will be considered evaluable if: They have completed the exposure diary (only for the exposed group). They have responded to the medical history questionnaire. They have undergone sampling of oral mucosa exfoliated cells and blood collection. ;

Related Conditions & MeSH terms

• Cytotoxicity

• NCT number: NCT06343103
• Study type: Interventional
• Source: European Institute of Oncology
• Contact: Emanuela Omodeo Salè
• Phone: +39 02 57489051
• Email: eomodeo@ieo.it
• Status: Recruiting
• Phase: N/A
• Start date: August 2, 2022
• Completion date: December 31, 2025